EXPERIMENTAL
All melting points were determined on an electrothermal apparatus (Büchi 535, Switzerland) in an open capillary tube and were uncorrected. Elemental analyses were performed on a Yanaco CHNS Corder elemental analyzer (Japan). IR spectra (u, cm -1 ) were recorded in KBr pellets on a PA-9721 IR spectrophotometer (Shimadzu, Japan). 1 H NMR and 13 C NMR spectra were obtained on a Jeol 300 MHz (Japan) spectrometer in DMSO-d 6 as solvent, using TMS as internal reference, and chemical shifts (d) are expressed in ppm. Mass spectra were recorded on Kratos (75 eV) MS equipment (Germany).
Synthetic pathways are presented in Schemes 1-3 and physicochemical and spectral data of the synthesized compounds are given in Tables I and II. 2-Amino-3-cyclohexylideneprop-1-ene-1,1,3-tricarbonitrile (1) was synthesized according to the literature procedure (11) . Compounds 4a,b and 6a,b were formed through non-isolable intermediates 3a,b and 5a,b, respectively. (2) . -To a solution of compound 1 (0.212 g, 1 mmol) in ethanol (40 mL), piperidine (0.5 mL) and benzaldehyde (0.106 g, 1 mmol) were added. The reaction mixture was heated under reflux for 3 h, then poured onto an ice/water mixture containing a few drops of hydrochloric acid. The formed solid product was collected by filtration.
Syntheses 2-Amino-3-(2-benzylidenecyclohexylidene)prop-1-ene-1,1,3-tricarbonitrile

3-Amino-4-(1-amino-2,2-dicyanovinyl)-1-phenyl-5,6,7,8-tetrahydro-1-phenylnaphthalene-2 -carbonitrile (4a) and ethyl 3-amino-4-(1-amino-2,2-dicyanovinyl)-5,6,7,8-tetrahydro-1-phenylnaphthalene-2-carboxylate (4b). General procedure. -Method A.
To a solution of compound 2 (0.3 g, 1 mmol), either malononitrile (0.066 g, 1 mmol) or ethyl cyanoacetate (0.113 g, 1 mmol) was added in ethanol (40 mL) containing triethylamine (0.50 mL). The reaction mixture was heated under reflux for 3 h, then poured onto an ice/water mixture containing a few drops of hydrochloric acid. The solid product formed in each case was collected by filtration. Method B. To a solution of compound 1 (0.212 g, 1 mmol) in ethanol (40 mL) containing a catalytic amount of triethylamine (0.50 mL), either a-cyanocinnamonitrile (0.150 g, 1 mmol) or ethyl a-cyanocinnamate (0.201 g, 1 mmol) was added. The reaction mixture in each case was heated under reflux for 3 h, then neutralized by pouring onto an ice/ water mixture containing a few drops of hydrochloric acid. The solid product formed in each case was collected by filtration. (2,3-diamino-1-phenyl-1,2,5,6,7,8-hexahydroisoquinolin-4- 
2-(Amino
-To a solution of compound 2 (0.30 g, 1 mmol) in ethanol (40 mL), either hydrazine hydrate (0.050 g, 1 mmol) or phenylhydrazine (0.108 g, 1 mmol) was added. The reaction mixture in each case was heated under reflux for 3 h, then poured onto an ice/water mixture containing a few drops of hydrochloric acid. The formed solid product in each case was collected by filtration.
2-Amino-3-(2-benzylidene-6-bromocyclohexylidene)prop-1-ene-1,1,3-tricarbonitrile (7) . -A solution of compound 2 (0.30 g, 1 mmol) in glacial acetic acid (30 mL) was warmed to 60 o C, then bromine solution (0.16 g, 1 mmol) in acetic acid (10 mL) was added dropwise under continuous stirring. The reaction mixture was stirred for 1.5 h, then poured into an ice/water mixture and the formed solid product was collected by filtration. (8) . -To a solution of compound 2 (0.30 g, 1 mmol) in ethanol (40 mL) containing triethylamine (0.50 mL), phenylisothiocyanate (0.135 g, 1 mmol) was added. The reaction mixture was heated under reflux for 3 h, then poured into an ice/ water mixture containing a few drops of hydrochloric acid. The formed product was collected by filtration. (9) . -To a cold solution (0-5 o C) of compound 1 (0.212 g, 1 mmol) in pyridine (15 mL), an equimolar amount of diazotized-4-methyl-benzenediazonium chloride was gradually added under stirring. The solid product separated during stirring in an ice bath was collected by filtration and washed thoroughly with water. 2-(Amino (2,3,5,6,7,8- 
4-(2-Benzylidenecyclohexylidene
)(cyano)methyl)-1,2,3,6-tetrahydro-6-imino-1-phenyl-2-thio- xopyrimidine-5-carbonitrile3-Amino-2-cyano-4-(2-(p-tolyl-hydrazono)-cyclohexylidene)prop-1-ene-1,1,3-tricarbonitrile
hexahydro-3-imino-2-p-tolylcinnoline-4-yl)methylene)malononitrile (10)
. -A suspension of compound 9 (0.33 g, 1 mmol) in sodium ethoxide solution (obtained by dissolving sodium metal (0.046 g, 0.2 mmol) in absolute ethanol (20 mL) was heated in boiling water for 2 h and then left to cool. The solid product formed upon pouring onto ice/water was collected by filtration. -2,3,5,6,7,8-hexahydrocinnolin-4-yl) methylene)malononitrile (11) . -A solution of compound 10 (0.330 g, 1 mmol) in ethanol (30 mL) containing one pellet of sodium hydroxide was heated under reflux for 3 h, then poured onto ice/ water containing a few drops of hydrochloric acid and the formed solid product was collected by filtration.
2-(Amino(3-oxo-2-(p-tolylamino)
3-Amino-3-(3,5-diamino-4H-pyrazol-4-ylidene)-2-cyclohexylidene-propanonitrile (12a) and 3-amino-3-(3-amino-5-imino-1-phenyl-1H-pyrazol-4-(5H)-ylidene)-2-cyclohexylidenepropanonitrile (12b).
-To a solution of compound 1 (0.212 g, 1 mmol) in ethanol (40 mL), either hydrazine hydrate (0.05 g, 1 mmol) or phenylhydrazine (0.108 g, 1 mmol) was added. The reaction mixture in each case was heated under reflux for 3 h and then poured onto an ice/water mixture containing a few drops of hydrochloric acid. The solid product formed in each case was collected by filtration. 
Antitumor activity tests
Fetal bovine serum (FBS) and L-glutamine were from Gibco Invitrogen Co. (UK). RPMI-1640 medium was from Cambrex (USA), dimethyl sulfoxide (DMSO), doxorubicin, penicillin, streptomycin and sulforhodamine B (SRB) were from Sigma Chemical Co. (USA).
Three human tumor cell lines, MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer) and SF-268 (CNS cancer) were used. MCF-7 was obtained from the European Collection of Cell Cultures (ECACC, UK) and NCI-H460 and SF-268 were kindly provided by the National Cancer Institute (NCI, Cairo, Egypt). Their growth as a monolayer was routinely maintained in RPMI-1640 medium supplemented with 5 % heat inactivated FBS, 2 mmol L -1 glutamine and antibiotics (penicillin 100 U mL -1 , streptomycin 100 mg mL -1 ), at 37 o C in a humidified atmosphere containing 5 % CO 2 . Exponentially growing cells were obtained by plating 1.5´10 5 cells mL -1 for MCF-7 and SF-268 and 0.75´10 4 cells mL -1 for NCI-H460, followed by 24 h of incubation. The effect of the vehicle solvent (DMSO) on the growth of these cell lines was evaluated in all experiments by exposing untreated control cells to the maximum concentration (0.5 %) of DMSO used in each assay.
The effects of compound 2-12b on the in vitro growth of human tumor cell lines were evaluated according to the procedure adopted by the National Cancer Institute (NCI, USA) in the 'In vitro Anticancer Drug Discovery Screen' which uses the protein-binding dye sulforhodamine B to assess cell growth (12) . Briefly, cells growing exponentially in 96-well plates were then exposed for 48 h to five serial concentrations of each compound, starting from a maximum concentration of 150 mmol L -1 . Following this exposure period, adherent cells were fixed, washed and stained. The bound stain was solubilized and the absorbance was measured at 492 nm in a plate reader (Powerwave XS, Bio-Tek Instruments Inc., USA). For each test compound and cell line, a dose-response curve was obtained and the growth inhibition of 50 % (GI 50 ), corresponding to the concentration of the compounds that inhibited 50 % of net cell growth, was calculated as described elsewhere (13) . Doxorubicin was used as a positive control and was tested in the same manner.
RESULTS AND DISCUSSION
Chemistry
The reaction of compound 1 with benzaldehyde gave the benzal derivative 2, the structure of which was established on the basis of analytical and spectral data. The 1 H NMR spectrum showed the presence of a multiplet at d 2.22-2.24 and 2.30-2.34 ppm coresponding to four CH 2 groups, a singlet at d 3.65 ppm (D 2 O exchangeable corresponding to the NH 2 group) and a singlet at d 6.98 ppm for the CH=C proton. Moreover, the 13 The reactivity of the latter product with cyanomethylene reagents was studied. Thus, the reaction of compound 2 with either malononitrile or ethyl cyanoacetate gave the tetrahydronaphthalene derivatives 4a,b. The latter products were formed through intermediate formation of compounds 3a,b (Scheme 1). Compounds 4a and 4b were obtained through another reaction route as well. Thus, the reaction of compound 1 with either a-cyanocinnamonitrile or ethyl a-cyanocinnamate gave the same tetrahydronaphthalene derivatives 4a and 4b (m.p. and mixed m.p.), respectively (Scheme 1). The analytical and spectral data (Tables I and II) of the latter products are consistent with the proposed structures (see experimental section).
On the other hand, the reaction of compound 2 with either hydrazine hydrate or phenylhydrazine gave the hyrazide derivatives 6a,b through intermediate formation of 5a,b.
The reaction of compound 2 with bromine in glacial acetic acid gave the monobromo derivative 7. The reaction of compound 2 with phenylisothiocynate gave the pyrimidine derivative 8. The analytical and spectral data of 7 and 8 (Tables I and II) are in agreement with the proposed structures (Scheme 2). The reaction of compound 1 with 4-methylbenzenediazonium chloride gave the hydrazone derivative 9. The structure of compound 9 was also based on analytical and spectral data. Thus the 1 H NMR spectrum showed two multiplets at d 2.22-2.28 and 2.33-2.37 ppm for four methylene groups, one Compound 9 underwent ready cyclization in sodium ethoxide solution to give the pyridazine derivative 10 (Scheme 3). The 6-imino group in compound 10 underwent ready hydrolysis when heated in ethanolic sodium hydroxide to give the 6-oxopyridazine derivative 11 (Scheme 3). Such hydrolysis of an imino group into an oxo group had been reported before (14, 15) . The reaction of compound 2 with either hydrazine hydrate or phenylhydrazine gave the pyrazole derivatives 12a and 12b, respectively (Scheme 3). It is interesting to note that all compounds synthesized in this work can exist in either Z or E structures. However, according to the concept of push-pull alkenes reviewed by Sandstrom (16) , conjugated systems with unsaturated heterocyclic rings with conjugated alkyl chains, exemplify typical push-pull compounds, which can exist in Z/E equilibrium depending on the temperature and the nature of solvent. One can say that all the newly synthesized compounds in this work are typical push-pull compounds existing in Z/E equilibrium. 
Antitumor activity
The effect of compounds 1, 2, 4a, 4b, 6a, 6b, 7, 8, 9 , 10, 11, 12a and 12b was evaluated on the in vitro growth of three human tumor cell lines, namely, breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268), after continuous exposure for 48 h. The results are summarized in Table III. All compounds were able to inhibit the growth of the three human tumor cell lines in a dose-dependent manner (data not shown). The 2-(amino(3-phenylamino-1-phenyl--2-(phenylamino)-1,2,5,6,7,8-hexahydroisoquinolin-4-yl)methylene)malononitrile (6b) and the 3-amino-3-(3,5-diamino-4H-pyrazol-4-ylidene)-2-cyclohexylidene-propanenitrile (12a) exhibited the highest inhibitory effect on the three tumor cell lines, but still much lower than that of the control doxorubicin. On the other hand, compounds 4a, 7 and 12b showed a moderate growth inhibitory effect. Comparing the activities of 6a and 6b, it was assumed that the N-phenyl group in 6b coused weaker growth inhibitory effect although the results in the NCI-H460 cell line were comparable. Moreover, it is convenient to compare the activity of 3-amino-3-(3,5-diamino-4H-pyrazol-4-ylidene)-2-cyclohexylide- nepropanenitrile (12a) with that of 3-amino-3-(3-amino-5-imino-1-phenyl-1H-pyrazol--4-(5H)-ylidene)-2-cyclohexylidenepropanenitrile (12b): the former compound (with pyrazole moiety) showed higher inhibitory effect than the latter (with N-pyrazole moiety).
CONLUSIONS
In this work, we described a new series of tetrahydronaphthalene, hexahydrophthalazine and hexahydrocinnoline derivatives obtained starting from the 2-amino-3-cyclohexylidene-1-propen-1,1,3-tricarbonitrile. Some of synthesized products showed potential anti-tumor activity. This finding encourages us to explore new molecules by introducing potent moieties, such as heterocyclic and fused ring systems described in this work, into other enaminonitriles. Our prediction is that these compounds with new ring systems may show better antitumor activity.
